KIT LAI: Open Payments
NPI 1063988798 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 29 payments from 13 companies in 2025. Trend: 2023 $1,160 · 2024 $976 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $226 |
| Ipsen Biopharmaceuticals, Inc | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Gilead Sciences, Inc. | 2 | $33 |
| GENZYME CORPORATION | 1 | $26 |
| Ardelyx, Inc. | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Janssen Biotech, Inc. | 1 | $20 |
| Abbott Laboratories | 1 | $18 |
Products named: SKYRIZI, RINVOQ, IQIRVO, ENTYVIO, LINZESS, DUPIXENT, IBSRELA, REZDIFFRA.
Industry payments across AZ — which companies pay providers there.
